TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05988801

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resin based sealant
Description: resin-based sealant material
Study: NCT06250803

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: early pancreatic stent placement (EPSP)
Description: In the EPSP group, a single pig-tail pancreatic stent (5Fr) will be inserted instantly after ERC or EST, and subsequent biliary procedures will proceed as planned. In contrast, in the LPSP group, while keeping the PD guidewire in place, a single pig-tail PD stent (5Fr) will be ultimately placed after all completion of therapeutic biliary procedures, e.g. biliary stone removal or drainage.

Intervention type: DEVICE
Group type: OTHER
Intervention: early pancreatic stent placement (EPSP)
Description: In the EPSP group, a single pig-tail pancreatic stent (5Fr) will be inserted instantly after ERC or EST, and subsequent biliary procedures will proceed as planned. In contrast, in the LPSP group, while keeping the PD guidewire in place, a single pig-tail PD stent (5Fr) will be ultimately placed after all completion of therapeutic biliary procedures, e.g. biliary stone removal or drainage.
Study: NCT04728516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan-based dual eradication therapy for two weeks
Description: Patients with ACS after PCI, associated with positive Hp need a long-term DAPT treatment. We conducted a study on the prevention of gastrointestinal bleeding between vonoprazan-based dual eradication therapy for two weeks and pantoprazole for six months of a rountine therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: amoxicillin
Description: amoxicillin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: Pantoprazole
Study: NCT05650918

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MesoPher
Description: autologous monocyte-derived dendritic cells loaded with PheraLys (tumor cell lysate)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mitazalimab
Description: agonistic human monoclonal (IgG1) antibody targeting CD40
Study: NCT05417724

Intervention type: OTHER
Group type: OTHER
Intervention: Battlefield Acupuncture
Description: Battlefield Acupuncture
Study: NCT05517941

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: active cycle breathing
Description: The active cycle breathing technique will involve three steps: breathing control, thoracic expansion exercise, and forced expiration technique, In breathing control, the patient will sit comfortably in a chair and breathe at a normal rate and depth using the lower chest. In the thoracic expansion exercise, the physical therapist rested his/her hands on the patient's epigastrium and guided the patient's breathing so that they breathed at a slow and deep rate using the lower chest, then held their breath for 2 s and fully exhaled; this was repeated two or three times, then the patient returned to breathing control. For the forced expiration technique, the physical therapist asked the patient to inhale deeply while simultaneously contracting the abdominal muscle and keeping the mouth and throat open. They then held their breath for 2 s, followed by vigorous exhalation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: active cycle breathing
Description: The active cycle breathing technique will involve three steps: breathing control, thoracic expansion exercise, and forced expiration technique, In breathing control, the patient will sit comfortably in a chair and breathe at a normal rate and depth using the lower chest. In the thoracic expansion exercise, the physical therapist rested his/her hands on the patient's epigastrium and guided the patient's breathing so that they breathed at a slow and deep rate using the lower chest, then held their breath for 2 s and fully exhaled; this was repeated two or three times, then the patient returned to breathing control. For the forced expiration technique, the physical therapist asked the patient to inhale deeply while simultaneously contracting the abdominal muscle and keeping the mouth and throat open. They then held their breath for 2 s, followed by vigorous exhalation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: incentive spirometer
Description: Incentive spirometry is accomplished by using a device that provides feedback when the patient inhales at a predetermined flow and sustains the inflation for at least 5 seconds. The patient is instructed to hold the spirometer in an upright position, exhale normally, and then place the lips tightly around the mouthpiece. The next step is a slow inhalation to raise the ball (flow-oriented) or the piston/ plate (volume-oriented) in the chamber to the set target. At maximum inhalation, the mouthpiece is removed, followed by a breath-hold and normal exhalation.
Study: NCT06437743

Intervention type: DEVICE
Intervention: Nociception Level (NoL) Monitor
Description: The NoL Monitor (PMD-200) is a multi-parameter sensor device placed on the patient's finger to estimate nociception levels during surgery. It provides continuous, real-time feedback to the anesthesiologist on the patient's nociception, assisting in the optimization of analgesic drug administration. The monitor integrates parameters such as heart rate variability, skin conductance, and other physiological signals to compute the NoL index, which ranges from 0 to 100, with target values between 10 and 25 for optimal nociception management.

Intervention type: DEVICE
Intervention: Nociception Level (NoL) Monitor
Description: The NoL Monitor (PMD-200) is a multi-parameter sensor device placed on the patient's finger to estimate nociception levels during surgery. It provides continuous, real-time feedback to the anesthesiologist on the patient's nociception, assisting in the optimization of analgesic drug administration. The monitor integrates parameters such as heart rate variability, skin conductance, and other physiological signals to compute the NoL index, which ranges from 0 to 100, with target values between 10 and 25 for optimal nociception management.
Study: NCT05376332

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonomyographic Prosthesis
Description: The sonomyographic system will include a custom-fitted test socket incorporating ultrasound transducers and controlling a TASKA prosthetic hand. All socket fittings will be performed by a board-certified prosthetist as part of this study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Myoelectric direct control prosthesis
Description: The direct control system will include a custom-fitted test socket incorporating dual-site electrodes and controlling a TASKA prosthetic hand. All socket fittings will be performed by a board-certified prosthetist as part of this study.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Myoelectric pattern recognition prosthesis
Description: The pattern recognition system will include the subject's clinically-prescribed socket and commercially-available pattern recognition technology (IBT Sense). The pattern recognition system will not be fitted as part of this study, as subjects will already be trained users prior to enrolling in the study.
Study: NCT04945057

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mindpax monitoring system
Description: All participants will use the Mindpax mobile application, wear the wrist accelerometer and fill in weekly self-assessments. All participants will obtain weekly health tips (general psychoeducation) and additional individualized targeted tips when the system detects deviation from individual mood, activity and sleep patterns, during the active 12 months of followup.
Study: NCT04824651

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: Vaccination done as part of France's COVID-19 Vaccination Campaign

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: Vaccination done as part of France's COVID-19 Vaccination Campaign

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: Vaccination done as part of France's COVID-19 Vaccination Campaign

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: Vaccination done as part of France's COVID-19 Vaccination Campaign

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: Vaccination done as part of France's COVID-19 Vaccination Campaign

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: Vaccination done as part of France's COVID-19 Vaccination Campaign

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: Vaccination done as part of France's COVID-19 Vaccination Campaign

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: Vaccination done as part of France's COVID-19 Vaccination Campaign

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: Vaccination done as part of France's COVID-19 Vaccination Campaign

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: Vaccination done as part of France's COVID-19 Vaccination Campaign

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: Vaccination done as part of France's COVID-19 Vaccination Campaign

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: Vaccination done as part of France's COVID-19 Vaccination Campaign

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: Vaccination done as part of France's COVID-19 Vaccination Campaign

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: Vaccination done as part of France's COVID-19 Vaccination Campaign

Intervention type: BIOLOGICAL
Intervention: COVID-19 vaccine
Description: Vaccination done as part of France's COVID-19 Vaccination Campaign
Study: NCT05857475

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP therapy
Description: Continous positive airway pressure therapy

Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No CPAP
Study: NCT04495608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Fluconazole 50 mg/capsule or placebo, per os during 18 weeks :~* From W0 to W2 : 1 caps/ day~* From W2 to W4 : 1 or 2 caps/day~* From W4 to W6 : 1, 2 or 3 caps/day~* From W6 to W18 : 1, 2, 3 or 4 caps/day~The number of capsules to take will be determined by 24-hours calciuria results performed every 2 weeks during the titration period (W2, W4 and W6).~During the titration period, if 24-hours calciuria is \> 0.1 mmol/kg/day, fluconazole dose will be increased every 2 weeks to 50 mg per intake, with a maximum dose of 200 mg/day. If 24-hour calciuria is ≤ 0.1mmol/kg/day, fluconazole dose will remain stable.~After W6 and until the end of the study, the treatment dose will remain stable (stable period).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (1, 2, 3 or 4 pills to take daily during 18 weeks), same appearance to experimental drug
Study: NCT06451198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indobufen
Description: Patients meeting the criteria are randomized before discharge from the hospital and given indobufen 100mg bid and ticagrelor 90mg bid the second day after randomization. The administration shall last 12 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Patients meeting the criteria are randomized before discharge from the hospital and continued aspirin 100 mg qd and ticagrelor 90mg bid. The administration shall last 12 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: All the patients meeting the criteria and enrolled in the study are given ticagrelor 90mg bid for 12 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Description: All the patients meeting the criteria and enrolled in the study are given ticagrelor 90mg bid for 12 months.
Study: NCT05131724

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treadmill training with virtual reality
Description: The virtual environment will be composed of obstacles, different paths, and narrow and deviated corridors. Walking through this environment will require the infant to coordinate walking behaviour and adjust the length, height, and width of steps to negotiate the obstacles on the television screen placed at the infant's eye level in front of the treadmill. The speed, orientation, size, frequency of appearance, and shape of the obstacles will be manipulated according to individual performance following a standardized protocol. The virtual system will provide visual and auditory feedback on the success or failure of the activity to enhance motor learning. In addition, the characteristics of the environment (e.g., visibility, configuration, and distractions) will be adjusted to increase the complexity of the training.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treadmill training
Description: The RAM870A of the Medisoft treadmill will be used. Two treadmill training sessions will be held before the onset of the intervention to familiarize the children with the equipment. During these two sessions, the treadmill training and speed will be set according to the following procedures: the ground walking speed of each child will be determined through the baseline 6MWT, then the training velocity will be set at 50% of the maximum ground speed established during the 6MWT and increased gradually based on the tolerance of each child (i.e., no complaint of fatigue, heart rate not exceeding 70% of the maximum heart rate, and a lack of gait shuffling, buckling or dragging steps more than 5 seconds during walking).
Study: NCT06464783

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Corrective Exercise Program
Description: Week 1st to 2nd: Corrective exercises +Core strengthening (2 sets 10 reps). Stretchings (30 sec hold, 3 reps).~Week 3rd to 5th: Corrective exercises +Core strengthening (3 sets 15 reps). Stretchings (30 sec hold, 3 reps).~Week 5th to 8th: Corrective exercises +Core strengthening (3 sets 20 reps). Stretchings (30 sec hold, 3 reps).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Exercise Program
Description: Week 1st to 2nd: Thoracic extension (2 sets 10 reps). Mobilization (60 sec 2 reps). Stretching (30 sec hold and 3 reps).~Week 3rd to 5th: Thoracic extension (2 sets 15 reps). T W Y I thoracic exercise in prone (2 sets 15 reps). Self-mobilization (60 seconds 2 reps). Stretching (30 sec hold and 3 reps)~Week 5th to 8th. Thoracic extension (3 sets 20 reps). T W Y I thoracic exercise in prone position (3 sets 20 reps). Self-mobilization (60 sec 2 reps). Stretching (30 sec hold and 3 reps)
Study: NCT06190197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics postoperatively.
Description: Prophylactic antibiotics postoperatively. All participants in this arm will receive nitrofurantoin 100 milligrams by mouth daily for either 10 or 21 days based on whether they had an ileal conduit or orthotopic neobladder, respectively, for the diversion. Participants will be instructed to swallow the capsule whole, preferably with food and at the same time each day. If a dose is forgotten, participants will be asked to take it when they remember and then take the next dose as usual. However, if they do not remember until the next dose, do not take extra capsules to make up the missed dose.
Study: NCT04772729

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin faster aspart (Fiasp, Novo Nordisk)
Description: Duration of the study: 10 weeks.~It is assumed that the patients will attend 4 visits in Pediatric Diabetology Clinic, and 3 telephone consultations.~W0: The study will start with a 2-week run-in period in order to normalize glycemia.~W1: RT-CGM will be inserted. Subsequently, the participants will be randomly assigned to one of two groups (Fa-A or A-Fa), basing on which the order of insulin use will be determined.~W2: after 2 weeks, diabetology telephone consultation (washout period).~W3: after 2 weeks, diabetology consultation. Changing insulin type according to the allocation.~W4: after 2 weeks, diabetology telephone consultation (washout period).~W5: after 2 weeks, diabetology telephone consultation.~W6: the results obtained throughout the study will be discussed with the patient and the parent.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin faster aspart (Fiasp, Novo Nordisk)
Description: Duration of the study: 10 weeks.~It is assumed that the patients will attend 4 visits in Pediatric Diabetology Clinic, and 3 telephone consultations.~W0: The study will start with a 2-week run-in period in order to normalize glycemia.~W1: RT-CGM will be inserted. Subsequently, the participants will be randomly assigned to one of two groups (Fa-A or A-Fa), basing on which the order of insulin use will be determined.~W2: after 2 weeks, diabetology telephone consultation (washout period).~W3: after 2 weeks, diabetology consultation. Changing insulin type according to the allocation.~W4: after 2 weeks, diabetology telephone consultation (washout period).~W5: after 2 weeks, diabetology telephone consultation.~W6: the results obtained throughout the study will be discussed with the patient and the parent.
Study: NCT06280482

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide riboside (NR)
Description: Participants will take their weight-based dose of NR once daily by mouth with food for 60 days.
Study: NCT05334186

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Reasoning Training
Description: The current study is explores the feasibility and preliminary relative effectiveness of a telehealth-delivered inductive reasoning intervention. The results of the study can help to provide insight on whether a telehealth-adapted reasoning training shows promise with older adults and can also be used to power future clinical trial studies to more definitively evaluate the effectiveness of telehealth delivered training.
Study: NCT04730843

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ES102
Description: ES102 is administered via intravenous injection once every 21 days, every 21 days as a treatment cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ES102
Description: ES102 is administered via intravenous injection once every 21 days, every 21 days as a treatment cycle.
Study: NCT04817111

Intervention type: DRUG
Group type: OTHER
Intervention: MIB-626
Description: Two (2) 500 mg Tablets, By Mouth, Daily
Study: NCT04986397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cold Therapy
Description: A Breg Polar Care Cube with WrapOn Polar Pad, Back will be filled with ice chips and water per manufacturer instructions and applied to the abdomen.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard post-operative analgesia without the use of cryotherapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard post-operative analgesia without the use of cryotherapy.
Study: NCT05590286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan Tablets
Description: Vonoprazan 20 mg, tablets, orally，QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin Capsules
Description: Amoxicillin 750mg, Capsules ,orally，QID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin Capsules
Description: Amoxicillin 750mg, Capsules ,orally，QID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Esomeprazole 20mg, Capsules ,orally，BID
Study: NCT05468268

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 20 Hz rTMS
Description: rTMS stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Sham stimulation
Study: NCT06355778

Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic Resonance Imaging (MRI)
Description: Enrolled participants will have one MRI during the study on day 2 after having Day 1 visit. During the MRI the participants will complete various tasks.
Study: NCT06162299

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YS-HBV-002
Description: YS-HBV-002, A recombinant hepatitis B vaccine with PIKA adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YS-HBV-002
Description: YS-HBV-002, A recombinant hepatitis B vaccine with PIKA adjuvant

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: YS-HBV-002
Description: YS-HBV-002, A recombinant hepatitis B vaccine with PIKA adjuvant
Study: NCT04961788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemox combimed PD1 antibody
Description: 1. Toripalimab (240mg) intravenously, the administration time is 60 (+15) minutes, Q3W is administered once.~2. Gemox chemotherapy D1: oxaliplatin 85mg/m2, gemcitabine 1g/m2 D8: Gemcitabine 1g/m2 Three weeks is a course of treatment, a total of 6-8 courses.
Study: NCT06330038

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol will be used for the induction and maintenance of general anesthesia.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled anesthetics
Description: Inhaled anesthetics will be used for the maintenance of general anesthesia.
Study: NCT04800536

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rapidly declining plasma glucose
Description: Acute plasma glucose decline, divided into the following three phases: 1) Hyperglycaemic phase (plasma glucose 15 mmol/l), 2) Rapid plasma glucose decline phase and 3) Euglycaemic phase (plasma glucose 4.5-5.5 mmol/l).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Slowly declining plasma glucose
Description: Acute plasma glucose decline, divided into the following three phases: 1) Hyperglycaemic phase (plasma glucose 15 mmol/l), 2) Slow plasma glucose decline phase and 3) Euglycaemic phase (plasma glucose 4.5-5.5 mmol/l).
Study: NCT05219188

Intervention type: RADIATION
Intervention: 3.7 mS, CT radiation
Description: Subjects will undergo dynamic contrast enhanced CT with an estimated radiation exposure of 3.7 mS

Intervention type: RADIATION
Intervention: 3.7 mS, CT radiation
Description: Subjects will undergo dynamic contrast enhanced CT with an estimated radiation exposure of 3.7 mS

Intervention type: RADIATION
Intervention: 3.7 mS, CT radiation
Description: Subjects will undergo dynamic contrast enhanced CT with an estimated radiation exposure of 3.7 mS

Intervention type: RADIATION
Intervention: 3.7 mS, CT radiation
Description: Subjects will undergo dynamic contrast enhanced CT with an estimated radiation exposure of 3.7 mS
Study: NCT04713865

Intervention type: PROCEDURE
Intervention: endovascular treatment
Description: The bare metal stent covers the deep femoral artery lower than 50%

Intervention type: PROCEDURE
Intervention: endovascular treatment
Description: The bare metal stent covers the deep femoral artery in 50-90%

Intervention type: PROCEDURE
Intervention: endovascular treatment
Description: The bare metal stent totally covers the deep femoral artery
Study: NCT06395727

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: traditional fentanyl dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocain
Description: lidocaine nebuliser and lidocaine spray targeting difficult swallowing
Study: NCT06129266

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral care with breastmilk
Description: No intervention will be applied to the control group other than oral care with sterile distilled water, which is routine clinical practice.